BIVI
Price
$1.08
Change
-$0.00 (-0.00%)
Updated
Jun 5, 04:51 PM (EDT)
Capitalization
20.23M
HOFBF
Price
$0.15
Change
+$0.06 (+60.00%)
Updated
Apr 14 closing price
Capitalization
83.98M
Interact to see
Advertisement

BIVI vs HOFBF

Header iconBIVI vs HOFBF Comparison
Open Charts BIVI vs HOFBFBanner chart's image
BioVie
Price$1.08
Change-$0.00 (-0.00%)
Volume$201
Capitalization20.23M
Hofseth Biocare ASA
Price$0.15
Change+$0.06 (+60.00%)
Volume$400
Capitalization83.98M
BIVI vs HOFBF Comparison Chart
Loading...
BIVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIVI vs. HOFBF commentary
Jun 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIVI is a Hold and HOFBF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 05, 2025
Stock price -- (BIVI: $1.09 vs. HOFBF: $0.16)
Brand notoriety: BIVI and HOFBF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BIVI: 24% vs. HOFBF: 8%
Market capitalization -- BIVI: $20.23M vs. HOFBF: $83.98M
BIVI [@Biotechnology] is valued at $20.23M. HOFBF’s [@Biotechnology] market capitalization is $83.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $318.09B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIVI’s FA Score shows that 1 FA rating(s) are green whileHOFBF’s FA Score has 0 green FA rating(s).

  • BIVI’s FA Score: 1 green, 4 red.
  • HOFBF’s FA Score: 0 green, 5 red.
According to our system of comparison, both BIVI and HOFBF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIVI’s TA Score shows that 6 TA indicator(s) are bullish.

  • BIVI’s TA Score: 6 bullish, 4 bearish.

Price Growth

BIVI (@Biotechnology) experienced а +4.81% price change this week, while HOFBF (@Biotechnology) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +9.95%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

BIVI is expected to report earnings on Nov 27, 2024.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HOFBF($84M) has a higher market cap than BIVI($20.2M). HOFBF YTD gains are higher at: 55.000 vs. BIVI (-45.500). BIVI has higher annual earnings (EBITDA): -22.65M vs. HOFBF (-67.94M). HOFBF (25.6M) and BIVI (24.4M) have equal amount of cash in the bank . BIVI has less debt than HOFBF: BIVI (382K) vs HOFBF (171M). HOFBF has higher revenues than BIVI: HOFBF (257M) vs BIVI (0).
BIVIHOFBFBIVI / HOFBF
Capitalization20.2M84M24%
EBITDA-22.65M-67.94M33%
Gain YTD-45.50055.000-83%
P/E RatioN/AN/A-
Revenue0257M-
Total Cash24.4M25.6M95%
Total Debt382K171M0%
FUNDAMENTALS RATINGS
BIVI vs HOFBF: Fundamental Ratings
BIVI
HOFBF
OUTLOOK RATING
1..100
330
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
78
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
9040
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BIVI's Valuation (18) in the null industry is somewhat better than the same rating for HOFBF (78). This means that BIVI’s stock grew somewhat faster than HOFBF’s over the last 12 months.

BIVI's Profit vs Risk Rating (100) in the null industry is in the same range as HOFBF (100). This means that BIVI’s stock grew similarly to HOFBF’s over the last 12 months.

BIVI's SMR Rating (96) in the null industry is in the same range as HOFBF (98). This means that BIVI’s stock grew similarly to HOFBF’s over the last 12 months.

HOFBF's Price Growth Rating (40) in the null industry is somewhat better than the same rating for BIVI (90). This means that HOFBF’s stock grew somewhat faster than BIVI’s over the last 12 months.

HOFBF's P/E Growth Rating (100) in the null industry is in the same range as BIVI (100). This means that HOFBF’s stock grew similarly to BIVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIVI
RSI
ODDS (%)
Bearish Trend 2 days ago
85%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
71%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BIVI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
FORA2.110.03
+1.37%
Forian
TCBIO20.000.06
+0.30%
Texas Capital Bancshares
ARRY6.98-0.03
-0.43%
Array Technologies
CCK97.36-0.84
-0.86%
Crown Holdings
OFIX10.90-0.13
-1.18%
Orthofix Medical

HOFBF and

Correlation & Price change

A.I.dvisor indicates that over the last year, HOFBF has been loosely correlated with BIVI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if HOFBF jumps, then BIVI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HOFBF
1D Price
Change %
HOFBF100%
N/A
BIVI - HOFBF
44%
Loosely correlated
-1.80%
ETXPF - HOFBF
38%
Loosely correlated
N/A
PHGE - HOFBF
35%
Loosely correlated
+2.40%
INNMF - HOFBF
23%
Poorly correlated
N/A
IGXT - HOFBF
14%
Poorly correlated
N/A
More